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Abstract
The HIV-1 plague continues unabatedly across sub-Saharan Africa. In Botswana and Swaziland,
nearly 40% of the entire adult population is already infected. No current program is capable of
slowing the advancing tide. An effective vaccine and widespread treatment are years, if not, decades
away. In this most urgent situation, I propose that pre-exposure chemoprophylaxis be studied as a
means to reduce the spread of HIV-1 among at-risk individuals.
In sub-Saharan Africa, the human immunodeficiency
virus type 1 (HIV-1) epidemic has reached staggering pro-
portions with infection rates in several urban areas
exceeding 35% of the adult population [1]. While there is
no question of the need for interventional strategies to
stem the overwhelming tide of new infections, there is
also no clear consensus as to what approaches might be
the most effective. Considerable attention has been
focused on the development of an immunoprophylactic
vaccine [2] particularly for application in developing
countries. Unfortunately, the first phase 3 studies of a can-
didate HIV vaccine failed to provide protection from
infection [3-5] and none of the remaining vaccine candi-
dates currently in clinical trials appear likely to induce
potent protective immunity [6]. Given HIV's propensity to
escape cellular and humoral responses[7,8], there exists
no clear approach or viral target for vaccine development.
The World Health Organization (WHO) is committed to
developing centers to treat those infected with HIV-1 in
areas hardest hit by the epidemic [9]. While these efforts
may ease the suffering of those already affected, it is not
clear they will have a broad impact on the HIV-1 epidemic
in the immediate future. Herein, I propose a novel inter-
ventional approach with the potential for immediate
impact: that is the administration of chemoprophylaxis to
uninfected individuals who live in areas with a high prev-
alence of HIV-1.
In Europe and the United States, chemoprophylaxis is rec-
ommended for health-care workers (HCW) exposed to
blood or body fluids from an HIV-infected patient
through percutaneous injury or mucous membrane expo-
sure. The risk of HIV-1 transmission from a blood-con-
taminated needle stick is estimated to be about 0.3%. One
study of HCW exposed to HIV-1 found that azidothymi-
dine (AZT) reduced infections by 81% (95% CI = 43%–
94%) [10]. In animal studies, chronic infection with sim-
ian immunodeficiency virus (SIV) was eliminated by 4-
week administration of a single agent, tenofovir, even
when treatment was delayed up to 24 hours after viral
inoculation [11,12].
Chemoprophylaxis for HIV has also been shown to be
effective in cases of vertical transmission. The results of
the first large-scale clinical trial of mother-to-child trans-
mission (MTCT), PACTG 076, showed that a regimen
based on AZT alone effectively reduced infant infection by
66% (22.6% of infants in the placebo group became
infected compared to 7.6% of the AZT group) [13]. Moth-
ers were placed on oral AZT beginning at 14 to 34 weeks
of gestation and given intravenous AZT during labor. Each
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newborn then received oral AZT for 6 weeks. The protec-
tive effect was not entirely attributable to AZT's modest
effect on maternal HIV-1 RNA viral load. This and other
studies confirm that chemoprophylaxis with a single drug
can potently reduce the rate of HIV-1 transmission [14]
and suggest that the efficacy with currently recommended
therapeutic regimens (two- and three-drug combinations)
may be even higher.
Clearly, there are many differences between these scenar-
ios and the requirements inherent in the prophylactic
treatment of a large population at continuous risk for HIV
exposure. A HCW or newborn (in the absence of breast-
feeding) is exposed only once to the virus and chemo-
prophylaxis is needed on an individual basis for 4 to 6
weeks. Chemoprophylaxis of a large population would be
widespread and ongoing, and would require treatment of
many individuals, but would carry the added benefit of
conferring protection on their sexual contacts. The success
of post-exposure prophylaxis is supported by studies of
HCW and MTCT and while the large-scale efficacy of pre-
exposure prophylaxis in large population is unknown, it is
reasonable to assume a similar degree of protection might
be afforded.
Of the 40 million people living with HIV-1 infection
throughout the world, more than 60% are in sub-Saharan
Africa [1]. Further, 30% of all HIV-1-infected individuals
reside within southern Africa, although this region has
less than 2% of the world's population. In two countries,
Botswana and Swaziland, HIV-1 prevalence for the entire
adult population is approaching 40%. If there is no
decline in prevalence or incidence rates of infection in
these countries, then the risk of acquiring HIV-1 among
those currently uninfected is enormous. Based on data
from a cohort of HIV discordant couples in Uganda, it is
estimated that the rate of male-to-female transmission is
0.0009 per act, while the rate of female-to-male transmis-
sion is 0.0013, with an overall HIV-1 heterosexual trans-
mission rate of 0.0011 per coital act [15]. If
chemoprophylaxis can reduce these rates by 80–90%,
then the rate of heterosexual transmission would fall to
approximately 1 in 10,000 per act. Over time, the preva-
lence of HIV-1 would decrease as fewer new cases
occurred, leading to a further reduction in the incidence of
infection.
Through collaborative efforts of pharmaceutical compa-
nies and scientists from the United States and Europe,
small numbers of HIV-infected individuals in developing
countries are now being given antiretroviral therapy.
While the drugs are being supplied at reduced cost, treat-
ment remains prohibitively expensive for the majority of
infected individuals. Moreover, administration of com-
plex HIV therapeutic regimens requires frequent clinical
monitoring, and physicians must be trained in the inter-
pretation of laboratory values and the proper actions to be
taken. While these treatment efforts represent an impor-
tant first step, it is perhaps overly optimistic to assume
that the WHO will reach its goal to have 3 million HIV-
infected people (<10% of all cases) in developing coun-
tries under treatment by the end of 2005 [16]. More likely
this outcome will take many years, if not decades, for the
countries of southern Africa to develop the infrastructure
to treat the majority of HIV-infected people.
Pre-exposure chemoprophylaxis, on the other hand, can
be administered at a lower cost and the regimens simpli-
fied. In one of many possible scenarios, HIV-uninfected
individuals could be identified by serologic screening and
prescribed AZT (Figure 1). Once on AZT, individuals
would periodically (every 3 to 6 months) be tested for
HIV-1 seroconversion. Concurrently, they would be edu-
cated on the risks of infection even while on prophylactic
treatment. HIV infection that occurs while an individual is
on chemoprophylaxis would necessitate the provision of
combination therapy.
There are many potential drawbacks to this strategy. While
the effect of incomplete adherence to treatment in the set-
ting of chronic HIV-1 infection is well documented, it is
not known whether the same outcome will result from
prophylactic HIV therapy. Drug-resistant virus will
undoubtedly develop in those who become HIV-infected
and continue to take only AZT (or any single drug). Viral
resistance could reduce the chances of treatment success
in that individual, and over time, the resistant virus could
replace the wild-type virus in the population at large. With
this in mind, drugs like nevirapine, which promote viral
resistance in chronically infected individuals after a single
dose [17,18], should be avoided in a prophylactic setting.
A more reasonable choice would be one of the nucleoside
analogue reverse transcriptase inhibitors (NRTIs), reserv-
ing other drugs with little cross-resistance to the selected
NRTI as the mainstay of treatment.
Behavior modifications may also result if people interpret
chemoprophylaxis as potent protection against HIV and
engage more frequently in high-risk activities. This con-
cern has been raised in the context of HIV vaccine trials
and has thus far not been substantiated. In fact partici-
pants in a recent HIV vaccine trial did not have an increase
in high-risk behavior, as some anticipated, but rather had
a decrease in intravenous drug use and needle sharing
[19]. Similarly, educational programs aimed at increasing
awareness of the purpose and limitations of chemoproph-
ylaxis may have a positive impact on high-risk behavior.
Pre-exposure prophylaxis, as suggested here, would be
administered to uninfected individuals for years toRetrovirology 2004, 1:16 http://www.retrovirology.com/content/1/1/16
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Outline of one possible, chemoprophylaxis scenario Figure 1
Outline of one possible, chemoprophylaxis scenario. High-risk individuals would be screened by serology for HIV-1 infection. 
Positive individuals would be referred to a treatment center, if available. Negative individuals would be offered enrollment in 
the chemoprophylaxis program. Once enrolled, individuals would receive education on HIV prevention and be prescribed 
AZT. Every 3–6 months, these participants would be serologically re-tested. If positive, the person would be removed from the 
program, offered education on prevention for positives, and referred to the treatment center. If negative, AZT would be con-
tinued. Those who decline repeat testing would be taken off AZT. In this way, only those who are uninfected or recently 
infected would be on AZT.
Serologic Screen
Negative Positive
Offer Chemoprophylaxis
& Education.
Offer Education
Presribe AZT &
Educate.
Negative Positive
At 3-6 months
Perform HIV Serology.
Continue AZT.
Every 3 months
Refer toTreatment Center
& Offer Education on
Prevention with Positives.
Refer toTreatment Center
& Offer Education on
Prevention with Positives.
Person declines.
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decades until the epidemic is contained or eliminated.
Consequently, strong consideration must be given to the
long-term toxicity of the drug(s) used. Newer NRTIs have
a low incidence of side effect profiles [20]. The currently
recommended dose of AZT, 600 mg per day, is much safer
than the dose, 1500 mg per day, used in the initial mono-
therapy studies [21,22]. Further, many anti-HIV-1 com-
pounds appear to be safe for use in pregnancy and do not
cause significant fetal harm [23]. While safety concerns
must be considered, lifelong chemoprophylaxis would
certainly be less toxic than lifelong combination therapy.
In short, for those with a great chance of becoming
infected, the risks of pre-exposure chemoprophylaxis do
not, a priori, outweigh the potential benefits.
One population that may be best suited for examination
of this hypothesis is female commercial sex workers
(FSW) in southern Africa. Behavior intervention pro-
grams, which include education and safer sex recommen-
dations, have had a dramatic effect on HIV-1 incidence in
Thailand and other areas [24,25]. Similar programs in
Uganda had no effect on HIV-1 transmission [26]. The
HIV-1 prevalence rate in FSW is >68% in some cities in
Africa [27]. Further, some hypothesize that this group is
the major node or linchpin for maintaining the epidemic
[28]. Several cohorts have previously been studied and
clearly, those FSW who are uninfected are at enormous
risk for HIV-1 infection. Chemoprophylaxis should be
studied in the context of traditional prevention programs.
It is worth recalling that chemoprophylaxis is currently
used to protect individuals and groups in many settings
[29]. Anti-influenza agents are often used to stop flu out-
breaks in nursing homes. Travelers to areas with endemic
malaria are given mefloquine to prevent infection with
Plasmodium spp. Individuals with a history of rheumatic
fever are maintained on penicillin for many years to pre-
vent re-infection with Group A streptococcus. Routine
practice already dictates that HIV-infected patients with
acquired immunodeficiency syndrome (AIDS) be given
antibiotics to prevent Pneumocystis jiroveci pneumonia,
toxoplasmic encephalitis, and Mycobacterium avium com-
plex infections. No precedent exists for administering
ongoing chemoprophylaxis to large populations of at-risk
individuals. However, the urgency of the HIV epidemic
and the absence of any effective measures for curbing new
infections mandate that novel strategies be considered.
With respect to all infectious diseases, the proverb "a
ounce of prevention is worth a pound of cure" certainly
holds true. In the case of HIV infection, the stakes are
much higher.
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